ArticleFrontiers in immunology2025
Phosphorylation-driven effector switching of Rab7 and Rab12 by the leucine-rich repeat kinase 1 in mast cells.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mast cells (MCs) mediate immune, allergic, and neuroinflammatory responses by releasing inflammatory mediators upon activation through the immunoglobulin E (IgE) receptor FcεRI or innate stimuli acting through Mas-related G protein coupled receptors (Mrgprs). We previously showed that Rab12 negatively regulates mediator release by recruiting the Rab-interacting lysosomal protein (RILP)-dynein complex to the secretory granules (SGs). Because Rab12 also interacts with the RILP-like proteins RILP-L1 and RILP-L2, we examined whether phosphorylation controls Rab12 distribution among its RILP family effectors. Methods: Pulldown assays were used to compare the effects of MC activation on Rab12 interactions with its effectors. Results: Here we show that activation by either IgE/antigen or the neuropeptide substance P, which binds to MRGPRX2, induces phosphorylation of the Rab GTPases Rab7 and Rab12. Phosphorylation of both GTPases was sensitive to protein kinase C (PKC) inhibition but resistant to inhibition of the leucine-rich repeat kinase 2 (LRRK2), a known Rab12 phosphorylating kinase. Furthermore, knockdown of the Leucine-Rich Repeat kinase 1 (LRRK1) suppressed phosphorylation of both Rab7 and Rab12, implicating LRRK1 in their phosphorylation by a PKC-dependent mechanism. Like phosphorylation by LRRK2, LRRK1-mediated phosphorylation of Rab12 increased its affinity for RILP-L1 and RILP-L2 while reducing binding to RILP. In contrast, LRRK1 phosphorylation of Rab7 enhanced its affinity for RILP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.